Systemic inflammatory responses, including changes in biomarkers such as C-reactive protein (CRP), neutrophil-to-lymphocyte ratio (NLR), and platelet-to-lymphocyte ratio (PLR), have been shown to be closely linked with the prognosis of various cancer types [5, 6]. This evidence concerns the gene CRP and cancer.